Seshadri  Neervannan net worth and biography

Seshadri Neervannan Biography and Net Worth

Chief Operating Officer Sesha has over 25 years of experience in the global development of novel therapeutics. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan (an AbbVie company), where he built strong and nimble early development functions to rapidly enable proofs of concept as well as a robust late-stage development organization for product approval and commercialization of small molecules and biologics. He also established industry-leading expertise in drug delivery technologies in multiple ocular, oral and dermal product development programs; regulatory filings; and approvals, including novel intraocular, sustained-release injectables (Ozurdex®, Durysta®), a multidose non-preserved drug product in a first-ever container-closure delivery system (Restasis MultiDose®), topical dermal products (Rhofade® Cream, Aczone® Gel 7.5%) and several Rx and OTC topical ophthalmic products.

Prior to joining Allergan in 2007, Sesha was Director, Pharmaceutics R&D at Amgen Inc., where he oversaw CMC functions and assisted in building early development functions, primarily focusing on a discovery-development interface to enable pipeline advancement. Earlier in his career, he was Senior Research Investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. He received his PhD in Pharmaceutical Chemistry from the University of Kansas. Sesha is active in community charity services and has served on the Board of Greater Irvine Chamber of Commerce, as well as on scientific advisory boards of non-profit organizations and start-up companies.

What is Seshadri Neervannan's net worth?

The estimated net worth of Seshadri Neervannan is at least $3.11 million as of March 18th, 2024. Neervannan owns 64,767 shares of Tarsus Pharmaceuticals stock worth more than $3,114,645 as of March 15th. This net worth approximation does not reflect any other assets that Neervannan may own. Additionally, Neervannan receives an annual salary of $759,200.00 as COO at Tarsus Pharmaceuticals. Learn More about Seshadri Neervannan's net worth.

How old is Seshadri Neervannan?

Neervannan is currently 56 years old. There are 5 older executives and no younger executives at Tarsus Pharmaceuticals. Learn More on Seshadri Neervannan's age.

What is Seshadri Neervannan's salary?

As the COO of Tarsus Pharmaceuticals, Inc., Neervannan earns $759,200.00 per year. Learn More on Seshadri Neervannan's salary.

How do I contact Seshadri Neervannan?

The corporate mailing address for Neervannan and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at ir@tarsusrx.com. Learn More on Seshadri Neervannan's contact information.

Has Seshadri Neervannan been buying or selling shares of Tarsus Pharmaceuticals?

Seshadri Neervannan has not been actively trading shares of Tarsus Pharmaceuticals during the last ninety days. Most recently, Seshadri Neervannan sold 4,879 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a transaction totalling $149,297.40. Following the completion of the sale, the chief operating officer now directly owns 64,767 shares of the company's stock, valued at $1,981,870.20. Learn More on Seshadri Neervannan's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, insiders at the sold shares 4 times. They sold a total of 24,496 shares worth more than $749,577.60. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 8.3% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 3/18/2024.

Seshadri Neervannan Insider Trading History at Tarsus Pharmaceuticals

See Full Table

Seshadri Neervannan Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Seshadri Neervannan's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $48.09
Low: $45.60
High: $48.23

50 Day Range

MA: $49.11
Low: $41.29
High: $56.94

2 Week Range

Now: $48.09
Low: $20.08
High: $57.28

Volume

487,715 shs

Average Volume

639,551 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05